1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 What Is This Report About? 7
2.2 Syringes and Needles Market Segmentation 7
2.3 Definitions of Markets Covered in the Report 8
3 Syringes and Needles Market, United States 9
3.1 Syringes and Needles Market, United States, Revenue ($m), 2007-2014 9
3.2 Syringes and Needles Market, United States, Revenue ($m), 2014-2021 11
3.3 Syringes and Needles Market, United States, Volume (Units), 2007-2014 13
3.4 Syringes and Needles Market, United States, Volume (Units), 2014-2021 15
3.5 Syringes and Needles Market, United States, Average Price ($), 2007-2021 17
3.6 Syringes and Needles Market, United States, Distribution Share by Revenue ($m), 2013-2014 18
3.7 Syringes and Needles Market, United States, Company Share by Revenue ($m), 2014 19
4 Overview of Key Companies in United States, Syringes and Needles Market 21
4.1 Becton, Dickinson and Company 21
4.1.1 Company Overview 21
4.2 B. Braun Melsungen AG 21
4.2.1 Company Overview 21
4.3 Nipro Corporation 21
4.3.1 Company Overview 21
4.4 Baxter International Inc. 22
4.4.1 Company Overview 22
4.5 Smiths Medical 22
4.5.1 Company Overview 22
4.6 Covidien plc 22
4.6.1 Company Overview 22
5 Syringes and Needles Market Pipeline Products 23
6 Financial Deals Landscape 24
6.1 Acquisition 24
6.1.1 Sagent Pharma May Sell Itself 24
6.1.2 ICU Medical Acquires Excelsior Medical for USD59.5 Million 26
6.2 Asset Transactions 28
6.2.1 Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 28
6.2.2 Medline Industries Acquires Assets of SwabFlush from ICU Medical for USD27 Million 30
6.3 Equity Offerings 32
6.3.1 Unilife to Raise USD45 Million in Private Placement of Shares 32
6.4 Partnerships 33
6.4.1 Enable Injections Enters into Partnership with Flextronics International 33
6.5 Venture Financing 34
6.5.1 PharmaJet Raises USD3.7 Million in Financing Round 34
6.5.2 PharmaJet Raises Additional USD2.2 Million in Financing Round 35
6.5.3 EndoChoice Raises USD57 Million in Venture Financing 36
7 Recent Developments 38
7.1 Corporate Communications 38
7.1.1 Sep 29, 2015: Anacor Pharmaceuticals Announces Presentations of Crisaborole Topical Ointment, 2% Phase 3 Pivotal Data at Two Upcoming Medical Conferences 38
7.1.2 Aug 25, 2015: Unilife Appoints Harry Hamill to the Board of Directors 38
7.1.3 Aug 03, 2015: Sagent Pharmaceuticals Board Appoints Allan Oberman as Chief Executive Officer 39
7.1.4 Aug 01, 2015: SPARC Receives Complete Response Letter from USFDA for Latanoprost NDA 40
7.1.5 Jun 03, 2015: Bristol-Myers Squibb to Present Data from 14 Abstracts on Orencia (abatacept) at the European League Against Rheumatism (EULAR) 2015 Annual Meeting 41
7.1.6 Apr 16, 2015: Sagent Pharmaceuticals Appoints Michael Logerfo as President 43
7.1.7 Apr 16, 2015: Shlomo Yanai Joins Sagent Pharmaceuticals Board of Directors 44
7.1.8 Apr 08, 2015: Unilife Appoints Dr. Richard Beckman as Chief Medical Officer 44
7.1.9 Mar 26, 2015: Sagent Pharmaceuticals Announces Leadership Changes 45
7.2 Financial Announcements 46
7.2.1 Feb 16, 2016: Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Results 46
7.2.2 Feb 09, 2016: Unilife Announces Financial Results For the Second Quarter of Fiscal Year 2016 48
7.2.3 Feb 03, 2016: BD Announces Results For 2016 First Fiscal Quarter 49
7.2.4 Nov 09, 2015: Unilife Announces Financial Results For the First Quarter of Fiscal Year 2016 50
7.2.5 Nov 04, 2015: BD Announces Results For 2015 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2016 Guidance 53
7.2.6 Oct 13, 2015: Spring Bank Pharmaceuticals Announces Presentation of Results from Phase I Clinical Trial Supporting the Novel Mechanism of Action of SB 9200 in Patients with Hepatitis C at The Liver Meeting 54
7.2.7 Sep 29, 2015: Motif Announces Presentation of Two Posters on Iclaprim at ID Week 2015 55
7.2.8 Sep 14, 2015: Unilife Corporation Announces Financial Results For the Fourth Quarter and Full Fiscal Year 2015 56
7.2.9 Aug 14, 2015: Retractable Technologies Reports Results as of June 30, 2015 59
7.2.10 Aug 06, 2015: BD Announces Results for 2015 Third Fiscal Quarter and Raises EPS Guidance for Fiscal 2015 60
7.2.11 Aug 04, 2015: Sagent Pharmaceuticals Reports Second Quarter 2015 Financial Results 62
7.2.12 Jul 29, 2015: Hospira Reports Second-Quarter 2015 Results 63
7.2.13 Jul 28, 2015: Centinel Spine Implants Its First STALIF MIDLINE II-Ti Device 65
7.2.14 May 15, 2015: Retractable Technologies Reports Improved Results for the First Quarter 2015 66
7.2.15 May 11, 2015: Unilife Announces Financial Results For Fiscal Year 2015 Third Quarter 67
7.2.16 May 07, 2015: BD Announces Results For 2015 Second Fiscal Quarter 68
7.2.17 May 05, 2015: Sagent Pharmaceuticals Reports First Quarter 2015 Financial Results 69
7.2.18 Apr 28, 2015: Hospira Reports First-Quarter 2015 Results 70
7.2.19 Apr 27, 2015: Medtronic Announces Consent Decree with FDA for the Synchromed Drug Infusion System 71
7.2.20 Apr 16, 2015: Arch Therapeutics' AC5 Compared Favorably vs. Commercially Available Combination Hemostat in Animal Study 73
7.2.21 Apr 07, 2015: Dualis MedTech and ReliantHeart Partner on Fully Implantable TET System for the HeartAssist5 LVAD 74
7.2.22 Apr 01, 2015: Retractable Technologies Reports Results for the Three and Twelve Months Ended December 31, 2014 74
7.2.23 Mar 02, 2015: Neuren receives FDA response to request for Breakthrough Therapy 75
7.2.24 Feb 19, 2015: Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Results 78
7.3 Legal And Regulatory 80
7.3.1 Jul 23, 2015: Sigma-Aldrich Meets Evolving Quality and Regulatory Needs with ISO 13485 Expansion, Provides Diagnostic Customers with Reliable Critical Raw Materials 80
7.3.2 May 21, 2015: Retractable Technologies Reports Recognition of Payment 81
7.3.3 May 01, 2015: Hospira Statement On FDA's Final Biosimilar Guidance Documents 81
7.3.4 Apr 27, 2015: Retractable Technologies Announces Amended Final Judgment and Notice of Appeal 82
7.3.5 Apr 21, 2015: Retractable Technologies Announces U.S. Supreme Court Decision - Denial of Writ of Certiorari 83
7.3.6 Apr 17, 2015: Regarding the Result of Inspection at Terumo CVS Ann Arbor Plant 83
7.3.7 Apr 13, 2015: Hope for Greater Access for Patients to Biosimilar Medicines 83
7.3.8 Feb 27, 2015: Hospira Provides Update On FDA Inspection At Its Facilities In US And India 84
7.4 Other Significant Developments 84
7.4.1 Nov 03, 2015: Sigma-Aldrich Reports Q3 2015 Sales Of $703 Million And Adjusted Diluted EPS Of $1.00 84
7.4.2 Sep 28, 2015: Esperion Therapeutics Provides Further Updates on ETC-1002 Global Phase 3 Strategy Following Receipt of End-of-Phase 2 Meeting Minutes 86
7.4.3 Sep 15, 2015: BD Named 2015 Outstanding Corporate Innovator Winner by Product Development and Management Association 87
7.4.4 May 07, 2015: Sigma-Aldrich Reports Q1 2015 Sales Of $676 Million And Adjusted Diluted EPS Of $1.06. Declares $0.23 Quarterly Dividend. 87
7.4.5 May 05, 2015: Lucigen Expands Technological Reach with Exclusive Sigma-Aldrich Distribution Agreement 89
7.4.6 Mar 19, 2015: Sigma-Aldrich Announces Exclusive Distribution Agreement with Roche 90
7.4.7 Mar 19, 2015: Roche announces global distribution agreement for its Biochemical Reagents product portfolio with Sigma-Aldrich 90
7.5 Product News 91
7.5.1 Oct 05, 2015: Galil Medical Launches New Family Of Cryoablation Needles 91
7.5.2 Apr 13, 2015: Cadence Announces New LaserSwiss Capability 91
7.6 Strategy And Business Planning 92
7.6.1 Jan 21, 2016: Singularity University and BD Announce Collaboration Dedicated to Address Global Healthcare Challenges 92
7.6.2 Jan 20, 2016: West and Noble Collaborate to Improve Patient Education and Training for Self-Injection Systems 93
7.6.3 Sep 28, 2015: Clinical Data Presented On Binimetinib And Encorafenib In Melanoma 93
7.6.4 Jul 13, 2015: BD Announces Sustainability Goals for 2020 96
7.6.5 Jul 08, 2015: BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 97
7.6.6 May 21, 2015: Cadence Announces Major Expansion of Wisconsin Facility 97
7.6.7 May 18, 2015: Haselmeier Group Announces the Relocation of Haselmeier in the United States 98
7.6.8 May 12, 2015: SAFC Expands Carlsbad, Calif. Facility to Support Commercial-Scale Gene Therapy Production, Testing and Filling 98
7.6.9 Apr 17, 2015: Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 99
7.6.10 Apr 06, 2015: Breakout Labs and Becton, Dickinson and Company Partner to Provide Capital and Expertise to Biomedical Startups 100
8 Appendix 101
8.1 Research Methodology 102
8.1.1 Coverage 102
8.1.2 Secondary Research 102
8.1.3 Primary Research 102
8.1.4 Company Share Analysis 103
8.1.5 Distribution Share Analysis 103
8.2 GlobalData Consulting 103
8.3 Contact Us 103
8.4 Disclaimer 104

1.1 List of Tables
Table 1: Syringes and Needles Market, United States, Revenue ($m), USD Constant, Historic, 2007-2014 10
Table 2: Syringes and Needles Market, United States, Revenue ($m), USD Constant, Forecast, 2014-2021 12
Table 3: Syringes and Needles Market, United States, Volume (Units), Historic, 2007-2014 14
Table 4: Syringes and Needles Market, United States, Volume (Units), Forecast, 2014-2021 16
Table 5: Syringes and Needles Market, United States, Average Price ($), Historic, 2007-2014 17
Table 6: Syringes and Needles Market, United States, Average Price ($), Forecast, 2014-2021 17
Table 7: Syringes and Needles Market, United States, Distribution Share by Revenue ($m), USD Constant, 2013-2014 18
Table 8: Syringes and Needles Market, United States, Company Share by Revenue ($m), USD Constant, 2014 20
Table 9: Syringes and Needles Market Pipeline Products 23
Table 10: Sagent Pharma May Sell Itself 24
Table 11: ICU Medical Acquires Excelsior Medical for USD59.5 Million 26
Table 12: Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 28
Table 13: Medline Industries Acquires Assets of SwabFlush from ICU Medical for USD27 Million 30
Table 14: Unilife to Raise USD45 Million in Private Placement of Shares 32
Table 15: Enable Injections Enters into Partnership with Flextronics International 33
Table 16: PharmaJet Raises USD3.7 Million in Financing Round 34
Table 17: PharmaJet Raises Additional USD2.2 Million in Financing Round 35
Table 18: EndoChoice Raises USD57 Million in Venture Financing 36

1.2 List of Figures
Figure 1: Syringes and Needles Market, United States, Revenue ($m), USD Constant, Historic, 2007-2014 9
Figure 2: Syringes and Needles Market, United States, Revenue ($m), USD Constant, Forecast, 2014-2021 11
Figure 3: Syringes and Needles Market, United States, Volume (Units), Historic, 2007-2014 13
Figure 4: Syringes and Needles Market, United States, Volume (Units), Forecast, 2014-2021 15
Figure 5: Syringes and Needles Market, United States, Company Share (%) 2014 19